{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:12Z","timestamp":1790108772267,"version":"4.0.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The pharmacology, pharmacokinetics, and role in therapy of fostemsavir in management of HIV-1 infection are reviewed, with an emphasis on clinical efficacy and safety data from phase 2 and phase 3 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Fostemsavir (Rukobia, ViiV Healthcare), is a prodrug of temsavir, a novel pyridine compound with potent activity against HIV-1. Fostemsavir, the first oral attachment inhibitor, was approved and granted the breakthrough therapy designation by the Food and Drug Administration for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in heavily treatment-experienced adults. As absorption of temsavir is not altered with increased gastric pH, patients may take acid suppressive agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxidation; therefore, coadministration of fostemsavir with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John\u2019s wort is contraindicated because it may result in significantly lower temsavir exposure, which can ultimately impair virologic response. The most common adverse reactions associated with fostemsavir use include nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, and sleep disturbance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Fostemsavir may be an effective option for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. Fostemsavir is a particularly attractive treatment option for patients who are no longer able to achieve viral suppression with use of currently available antiretroviral therapies and who are able to adhere to a twice-daily oral regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa416","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T15:14:15Z","timestamp":1612797255000},"page":"376-388","source":"Crossref","is-referenced-by-count":18,"title":["Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B","family":"Chahine","sequence":"first","affiliation":[{"name":"Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"2021021913075264400_CIT0001","author":"Centers for Disease Control and Prevention"},{"key":"2021021913075264400_CIT0002","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services"},{"key":"2021021913075264400_CIT0003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP2748","article-title":"A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease\/reverse transcriptase and co-receptor tropism database from 2003 to 2012","volume":"19","author":"Paquet","year":"2014","journal-title":"Antivir Ther"},{"key":"2021021913075264400_CIT0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000002241","article-title":"Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States","volume":"83","author":"Millham","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021913075264400_CIT0005","article-title":"OUP: set plain","author":"Trogarzo","year":"2020"},{"key":"2021021913075264400_CIT0006","author":"ViiV Healthcare"},{"key":"2021021913075264400_CIT0007","author":"Bristol-Myers Squibb"},{"key":"2021021913075264400_CIT0008","author":"ViiV Healthcare"},{"key":"2021021913075264400_CIT0009","author":"US Food and Drug Administration"},{"key":"2021021913075264400_CIT0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"2021021913075264400_CIT0011","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","article-title":"Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"key":"2021021913075264400_CIT0012","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021913075264400_CIT0013","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00513-13","article-title":"Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors","volume":"57","author":"Li","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021913075264400_CIT0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dkt412","article-title":"Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068","volume":"69","author":"Zhou","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021021913075264400_CIT0015","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/jac\/dky271","article-title":"Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir","volume":"73","author":"Alessandri-Gradt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021021913075264400_CIT0016","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/jac\/dkaa073","article-title":"Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir","volume":"75","author":"Bouba","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021913075264400_CIT0017","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jac\/dkaa034","article-title":"Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals","volume":"75","author":"Lepore","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021913075264400_CIT0018","article-title":"Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTE study","author":"Ackerman"},{"key":"2021021913075264400_CIT0019","doi-asserted-by":"crossref","first-page":"e01446-18","DOI":"10.1128\/JVI.01446-18","article-title":"Neutralization synergy between HIV-1 attachment inhibitor fostemsavir and anti-CD4 binding site broadly neutralizing antibodies against HIV","volume":"93","author":"Zhang","year":"2019","journal-title":"J Virol"},{"key":"2021021913075264400_CIT0020","article-title":"Single and multiple dose pharmacokinetics and safety in non-HIV-infected healthy subjects dosed with BMS-663068, an oral HIV attachment inhibitor","author":"Nettles"},{"key":"2021021913075264400_CIT0021","article-title":"The effect of food on the pharmacokinetics of the HIV-1 attachment inhibitor temsavir, the active moiety of the prodrug fostemsavir","author":"Sevinsky"},{"key":"2021021913075264400_CIT0022","article-title":"Pharmacokinetics, metabolism, and urine of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects","author":"Gorycki"},{"key":"2021021913075264400_CIT0023","article-title":"Fostemsavir drug-drug interaction profile, an attachment inhibitor and oral prodrug of temsavir, for heavily treatment-experienced HIV-1 infected patients","author":"Moore"},{"key":"2021021913075264400_CIT0024","doi-asserted-by":"crossref","article-title":"Pharmacokinetics of temsavir, the active moiety of the prodrug fostemsavir, in subjects with hepatic impairment","author":"Sevinsky","DOI":"10.1093\/ofid\/ofx163.1086"},{"key":"2021021913075264400_CIT0025","article-title":"Impact of mild, moderate, and severe renal impairment and hemodialysis on temsavir pharmacokinetics following oral administration of fostemsavir, an attachment inhibitor for heavily treatment experienced HIV-1 infected patients","author":"Moore"},{"key":"2021021913075264400_CIT0026","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J Infect Dis"},{"key":"2021021913075264400_CIT0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QAI.0b013e31829726f3","article-title":"Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068","volume":"64","author":"Ray","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021913075264400_CIT0028","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/AAC.02503-15","article-title":"Model-based phase 3 dose selection for HIV-1 attachment inhibitor prodrug BMS-663068 in HIV-1-infected patients: population pharmacokinetics\/pharmacodynamics of the active moiety, BMS-626529","volume":"60","author":"Landry","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021913075264400_CIT0029","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3018(15)00177-0","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial","volume":"2","author":"Lalezari","year":"2015","journal-title":"Lancet HIV"},{"key":"2021021913075264400_CIT0030","doi-asserted-by":"crossref","article-title":"HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.","author":"Brinson","DOI":"10.7448\/IAS.17.4.19529"},{"key":"2021021913075264400_CIT0031","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3851\/IMP3112","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a phase IIb, randomized controlled trial","volume":"22","author":"Thompson","year":"2017","journal-title":"Antivir Ther"},{"key":"2021021913075264400_CIT0032","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0000000000001602","article-title":"Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir","volume":"77","author":"Lataillade","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021913075264400_CIT0033","article-title":"Long-term safety and efficacy of fostemsavir in treatment-experienced participants living with HIV-1","author":"Thompson"},{"key":"2021021913075264400_CIT0034","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 Infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021913075264400_CIT0035","article-title":"Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study)","author":"Lataillade"},{"key":"2021021913075264400_CIT0036","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2352-3018(15)00160-5","article-title":"BMS-663068, a safe and effective HIV-1 attachment inhibitor","volume":"2","author":"Ballana","year":"2015","journal-title":"Lancet HIV"},{"key":"2021021913075264400_CIT0037"},{"key":"2021021913075264400_CIT0038","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12763","article-title":"Effects of temsavir, active moiety of antiretroviral agent fostemsavir, on QT interval: results from a phase I study and an exposure-response analysis","author":"Lagishetty","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2021021913075264400_CIT0039","author":"Rukobia"},{"key":"2021021913075264400_CIT0040","first-page":"19530","article-title":"Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis","volume-title":"J Int AIDS Soc","author":"Lalezari","year":"2014"},{"key":"2021021913075264400_CIT0041","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1128\/AAC.04914-14","article-title":"Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects","volume":"59","author":"Zhu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021913075264400_CIT0042","article-title":"No clinically significant drug interaction when BMS-663068, a novel HIV-1 attachment inhibitor, is coadministered with tenofovir disoproxil fumarate","author":"Zhu"},{"key":"2021021913075264400_CIT0043","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bcp.13964","article-title":"Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants","volume":"85","author":"Moore","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2021021913075264400_CIT0044","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1060028018793252","article-title":"HIV clinical updates: new single-tablet regimens","volume":"53","author":"Sebaaly","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2021021913075264400_CIT0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"2021021913075264400_CIT0046","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/14656566.2019.1570131","article-title":"Choosing appropriate pharmacotherapy for drug-resistant HIV","volume":"20","author":"Capetti","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"2021021913075264400_CIT0047","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/jac\/dkaa178","article-title":"In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients","volume":"75","author":"Saladini","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021913075264400_CIT0048","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1521\/aeap.2014.26.6.521","article-title":"Adherence to antiretroviral therapy among HIV-infected adults in the United States","volume":"26","author":"Beer","year":"2014","journal-title":"AIDS Educ Prev"},{"key":"2021021913075264400_CIT0049","author":"Rukobia"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/5\/376\/36320787\/zxaa416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/5\/376\/36320787\/zxaa416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T04:38:07Z","timestamp":1613882287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/5\/376\/6129458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,18]]},"published-print":{"date-parts":[[2021,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa416","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,2,18]]}}}